Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
arcticnovartis
Mon, 12/11/2023 – 07:19
Read more about Novartis inves…
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
arcticnovartis
Mon, 12/11/2023 – 01:34
Read more …
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
arcticnovartis
Fri, 12/08/2023 – 15:19
Read more about Latest Nov…
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
arcticnovartis
Wed, 12/06/2023 – 01:19
Read more about Novartis rece…
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
arcticnovartis
Tue, 11/28/2023 – 07:04
Read more about Novartis upgrades mid-term sales growth guidance, sho…
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
arcticnovartis
Tue, 11/28/2023 – 07:04
Read more about Novartis upgrades mid-term sales growth guidance, sho…
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
arcticnovartis
Mon, 11/20/2023 – 07:19
Read more about Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS a…
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
arcticnovartis
Mon, 11/20/2023 – 07:19
Read more about Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS a…
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
arcticnovartis
Thu, 11/09/2023 – 17:04
Read more about Novartis data show potential of …
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
arcticnovartis
Thu, 11/09/2023 – 17:04
Read more about Novartis data show potential of …
